Silicon Valley Bank offers new tool to value biotech startups

New data by Silicon Valley Bank’s http://www.svb.com/ valuations group attempts to bring objectivity to the relatively unscientific process of valuing early-stage biotech companies.

The challenge is that these companies are generally pre-revenue and potentially years away from profitability — if that’s in their future at all. Unknown factors such as timing, amount, price and terms of future rounds of financing make valuations something of a guessing game.

Silicon Valley / San Jose Business Journal – by Lindsay Riddell

Full Story: http://sanjose.bizjournals.com/sanjose/stories/2008/04/21/story11.html?b=1208750400^1622067